Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: PPLPHARMA

Piramal Pharma

Results filed 28 October 2026 · Market cap ₹31,807 crore

TurnaroundGuidance raisedPresentation only

Revenue
+28.1%
on a year ago
EBITDA
+119.8%
on a year ago
Profit to shareholders
Back to profit
from a loss a year ago
EBITDA margin
13.3%
+4.7 pts on last quarter

Piramal Pharma reported Q2FY27 consolidated revenue of Rs 2,617 Cr, representing 28% YoY growth, with EBITDA increasing 72% YoY to Rs 385 Cr and PAT turning marginally positive to Rs 5 Cr. Topline acceleration was led by the CDMO division (+36% YoY) with robust demand in ADC and on-patent manufacturing, alongside 32% YoY growth in Complex Hospital Generics aided by the Kenalog integration. Reflecting first-half performance, management upgraded its FY27 revenue growth guidance to 19%-20% with expected margin expansion, while preparing for the December 2026 expiry of the Bayer distribution agreement.

Piramal Pharma Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue2,6172,270+15.3%2,044+28.1%
Operating profit (EBIT)116−28.35n.m.−44.15n.m.
Operating margin4.4%-1.2%+567 bps-2.2%+658 bps
Other income35.9389.41−59.8%65.6−45.2%
Exceptional items00–0–
Profit before exceptional items and tax63.89−27.02n.m.−60.97n.m.
Profit to shareholders5.58−69.39n.m.−99.22n.m.
Share of joint ventures' and associates' profit17.7419.56−9.3%14.79+19.9%
Earnings per share (₹)0.04-0.52n.m.-0.75n.m.

Source: Piramal Pharma Limited’s filing to NSE, 27 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

These notes are from the presentation and press release. The concall transcript isn’t filed yet; the notes are rewritten when it is.

What stood out

  • Consolidated Q2FY27 revenue grew 28% YoY to Rs 2,617 Cr with EBITDA jumping 72% YoY to Rs 385 Cr, turning PAT positive to Rs 5 Cr vs a loss of Rs 99 Cr in Q2FY26
    SourcePress Release, page 2, Consolidated Financial Highlights table
  • Full-year FY27 outlook upgraded to 19% to 20% revenue growth with meaningfully higher profitability
    SourcePress Release, page 2: 'Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, we upgrade our FY27 outlook and now expect revenue growth of 19% to 20%, accompanied by meaningfully higher profitability.'
  • Bayer distribution agreement naturally expiring in December 2026; accounted for Rs 475 Cr in FY26 (~5% of revenue) at ~4.5% EBITDA margin
    SourceInvestor Presentation, page 18: 'Bayer Sales & Distribution Agreement: Natural Expiry in December 2026... Revenue in FY26 – Rs 475 Crores, Contribution to PPL consolidated turnover 5%... 4.5% EBITDA margin profile'

Guidance

MetricGuidancePeriod
Consolidated Revenue Growth
SourcePress Release, page 2: 'Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, we upgrade our FY27 outlook and now expect revenue growth of 19% to 20%'
19% to 20% YoYFY27
Consolidated Profitability
SourceInvestor Presentation, page 9: 'anticipate 19-20% revenue growth with meaningfully higher profitability.'
Meaningfully higher profitabilityFY27
Bayer Distribution Expiry Impact
SourceInvestor Presentation, page 18: 'Expected impact on FY27 revenue is low at less than 2%... Improvement in PPL Consolidated EBITDA margin excluding this Bayer Sales & Distribution revenue 50bps'
Less than 2% impact on FY27 revenue; ~50 bps improvement in Consolidated EBITDA margin excluding this revenueFY27

FY27 outlook was upgraded to 19%-20% revenue growth accompanied by meaningfully higher profitability, raised from earlier baseline guidance.

Tailwinds

  • CDMO revenue accelerated by 36% YoY in Q2FY27 and 28% YoY in H1FY27, supported by commercial demand, 22 new customer additions, and expansion of Phase III pipeline to 28 molecules
    SourceInvestor Presentation, pages 11 and 12: 'CDMO revenue grew 36% YoY to Rs 1,424 Cr in Q2FY27... Phase III molecules increased to 28 vs. 25 in March 2026.'
  • Rapid expansion in high-value CDMO segments, with ADC services up 51% YoY and on-patent commercial manufacturing up 39% YoY in H1FY27
    SourceInvestor Presentation, page 13: 'Contribution from Innovation Related Work 49%... Revenues from On-patent Commercial Manufacturing 39%... Revenues from ADC Services 51%'
  • Complex Hospital Generics grew 32% YoY in Q2FY27 supported by Kenalog integration and ex-US market traction in Sevoflurane
    SourcePress Release, page 2: 'CHG business complemented this momentum with 24% growth [in H1]... supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog'
  • Piramal Consumer Healthcare power brands and e-commerce channel expanded strongly by 21% YoY and 32% YoY respectively in H1FY27
    SourceInvestor Presentation, page 17: 'Power Brands continued to outperform, grew 21% in H1FY27; contributed 53% of PCH sales. E-commerce maintained strong momentum with 32% growth in H1FY27'

Headwinds

  • Net debt increased by Rs 695 Cr during H1FY27, from Rs 4,164 Cr as of March 31, 2026 to Rs 4,859 Cr as of September 30, 2026
    SourcePress Release, page 4, Consolidated Balance Sheet table
  • Bayer distribution contract expiration in December 2026 will cause a topline loss of around Rs 475 Cr on a full-year base (~5% of revenue)
    SourceInvestor Presentation, page 18: 'Bayer Contribution and Impact: Revenue in FY26 - Rs 475 Crores, Contribution to PPL consolidated turnover 5%'
  • Consolidated H1FY27 bottom line remains in net loss of Rs 64 Cr despite Q2 turning slightly profitable at Rs 5 Cr
    SourcePress Release, page 2, Consolidated Financial Highlights table: 'H1FY27 PAT (64) vs (181) H1FY26'

New businesses and products

acquisition · Acquired

Acquisition of controlling stake in Yapan Bio

Expected benefit
Strengthened biologics capabilities and platform
SourceInvestor Presentation, page 12: 'Strengthened biologics platform through the acquisition of a controlling stake in Yapan Bio.'

capacity expansion · On track; new microbiology laboratory commissioned

Lexington expansion for sterile fill-finish and ADC integration

Expected benefit
Adds sterile fill-finish capabilities, completing integrated ADC offering
Timeline
On track
SourcePress Release, page 3: 'The Lexington expansion remains on track, will add sterile fill-finish capabilities, completing the integrated ADC offering. Commissioned a new microbiology laboratory at the site.'

acquisition · Contributed to Q2FY27 revenues

Integration of Kenalog acquisition

Expected benefit
Expected to be an important growth catalyst for CHG in FY27
Timeline
FY27
SourceInvestor Presentation, page 16: 'Integrating Kenalog Acquisition - Contributed to Q2FY27 revenues; An important growth catalyst for FY27.'

new product · Launched

Launch of 'Vizible' premium skincare range under Lacto Calamine

Expected benefit
Strengthen presence in premium skincare and portfolio premiumization
Timeline
H1FY27
SourcePress Release, page 3: 'Introduced the Vizible range under Lacto Calamine to address rising demand for premium skincare products and strengthen portfolio premiumization.'

Things to check

  • Substantial rise in Net Debt during H1FY27 to Rs 4,859 Cr from Rs 4,164 Cr at FY26 end
    SourceConsolidated Balance Sheet, Press Release page 4 / Investor Presentation page 22: 'Net Debt 4,859 as of 30-Sep-26 vs 4,164 as of 31-Mar-26'
  • Topline headwind approaching from the natural expiry of Bayer Sales & Distribution agreement in December 2026
    SourceInvestor Presentation, page 18: 'Bayer Sales & Distribution Agreement: Natural Expiry in December 2026... Revenue in FY26 - Rs 475 Crores'

How the call went

Not yet: there’s no transcript.

Numbers against the story

Management's narrative highlights strong execution, operating leverage, and accelerating demand resulting in an upgraded 19-20% FY27 growth guidance. The reported revenue figures (+28% YoY) and EBITDA growth (+72% YoY) corroborate this operational momentum, with EBITDA margins expanding over 350 bps to 14.7% (company presentation) / 13.3% (excluding other income). However, the narrative omits commentary on balance sheet gearing, where net debt increased by Rs 695 Cr during the half year to Rs 4,859 Cr, and H1FY27 cumulative net profit remained negative at -Rs 64 Cr.

Sources

  • Investor presentation · filed Oct
  • Figures: the company’s results filing with NSE, linked under the table.

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.